Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Immunome today and set a price target of $40.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors tied to Immunome’s advancing clinical assets and differentiated platform strategy. He points to varegacestat’s strong desmoid tumor data, highlighting robust tumor volume reductions, durable disease control, and meaningful symptom relief that together support a best‑in‑class profile and a broader treatable population, including both progressive and non‑progressive lesions.

Maldonado also emphasizes the value of Immunome’s antibody‑drug conjugate franchise, noting management’s sophisticated, data‑driven design approach that tailors each ADC to specific tumor biology rather than relying on a generic template. With lead ROR1 ADC IM‑1021 moving through Phase 1/2 studies and multiple additional ADC IND filings anticipated, he views the underrecognized ADC pipeline and its first‑in‑class potential as key drivers of multi‑year growth, supporting his Buy rating and $40 price target.

Y. Maldonado covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, ImmunityBio, and Immunome. According to TipRanks, Y. Maldonado has an average return of 42.1% and a 57.29% success rate on recommended stocks.

In another report released on February 4, TipRanks – Google also upgraded the stock to a Buy with a $30.00 price target.